10.2 USP 795, 797 & 800 Integration
Key Takeaways
- Updated USP <795> assigns non-sterile Beyond-Use Dates by water activity and dosage form: non-preserved aqueous 14 days refrigerated; preserved aqueous 35 days; non-aqueous ORAL LIQUIDS 90 days; and all other non-aqueous dosage forms (including solids and non-aqueous topicals) 180 days.
- Compounding non-sterile preparations requires both a Master Formulation Record (MFR)—the detailed master recipe—and a Compounding Record (CR)—the lot-specific execution log detailing actual quantities, component lots, and personnel signatures.
- USP <797> classifies compounded sterile preparations into Category 1 (SCA; BUD ≤12 hours room temp or ≤24 hours refrigerated), Category 2 (cleanroom suite; BUDs up to 14–45 days depending on sterility testing and terminal sterilization), and Category 3 (cleanroom suite with advanced testing; BUDs up to 60–180 days).
- USP <800> mandates that hazardous drug (HD) compounding take place in a Containment Secondary Engineering Control (C-SEC) under negative pressure (-0.01 to -0.03 inches water column) with ≥12 or ≥30 ACPH and external venting.
- Personal Protective Equipment (PPE) for hazardous drugs requires two pairs of ASTM D6978 chemotherapy gloves (outer over cuff, inner under), a disposable back-closing chemotherapy gown changed every 2–3 hours, an N95 respirator, and mandatory Closed System Drug-Transfer Devices (CSTDs) for antineoplastic administration.
10.2 USP 795, 797 & 800 Integration
Quick Answer: Under Tennessee Board of Pharmacy enforcement, USP <795> governs non-sterile compounding, establishing Beyond-Use Dates (BUDs) strictly by water activity (a_w): 14 days refrigerated for non-preserved aqueous, 35 days for preserved aqueous, 90 days for non-aqueous oral liquids, and 180 days for all other non-aqueous dosage forms (solids and non-aqueous topicals alike). USP <797> classifies sterile compounding into Category 1 (SCA; BUD ≤ 12h room temp, ≤ 24h refrigerated), Category 2 (cleanroom suite; BUDs up to 14–45 days), and Category 3 (cleanroom suite with extended stability and sterility testing; BUDs up to 60–180 days). USP <800> governs hazardous drugs (HDs), requiring a negative pressure C-SEC (-0.01 to -0.03 in. w.c.) with external venting, Class II BSC / CACI C-PECs, two pairs of ASTM D6978 chemotherapy gloves, and mandatory Closed System Drug-Transfer Devices (CSTDs) for antineoplastic administration.
1. Harmonized Triad: Scope and Interplay of USP <795>, <797>, and <800>
The United States Pharmacopeia (USP) publishes general chapters that set nationwide standards for drug quality, purity, and safety. Under federal law and Tennessee Board of Pharmacy rules, USP chapters numbered below <1000> are legally binding and strictly enforceable:
┌─────────────────────────────────────────────────────────────────────────────┐
│ USP COMPOUNDING COMPLIANCE TRIAD │
├─────────────────────────────────────────────────────────────────────────────┤
│ USP <795>: PHARMACEUTICAL COMPOUNDING — NON-STERILE PREPARATIONS │
│ • Applies to non-sterile dosage forms (creams, ointments, oral liquids, │
│ suspensions, capsules, suppositories, troches). │
│ • Focuses on water activity (a_w), Master Formulation Records (MFR), │
│ Compounding Records (CR), and component chemical purity. │
├─────────────────────────────────────────────────────────────────────────────┤
│ USP <797>: PHARMACEUTICAL COMPOUNDING — STERILE PREPARATIONS │
│ • Applies to sterile dosage forms (IV infusions, injections, ophthalmic │
│ drops, tissue implants, aqueous bronchial inhalations). │
│ • Establishes Category 1, 2, and 3 classifications, cleanroom ISO zones, │
│ media-fill testing, and terminal sterilization validation. │
├─────────────────────────────────────────────────────────────────────────────┤
│ USP <800>: HAZARDOUS DRUGS — HANDLING IN HEALTHCARE SETTINGS │
│ • Overlays BOTH USP <795> and <797> when compounding with HAZARDOUS DRUGS. │
│ • Mandates containment engineering controls (C-PECs, C-SECs), negative │
│ pressure, external venting, PPE, and CSTD utilization. │
└─────────────────────────────────────────────────────────────────────────────┘
[!IMPORTANT] USP <800> does not replace USP <795> or <797>. Instead, it overlays them. If you compound a hazardous non-sterile drug (e.g., crushing finasteride tablets into an oral suspension), you must comply with both USP <795> and USP <800>. If you compound a hazardous sterile drug (e.g., preparing a methotrexate or cisplatin intravenous infusion), you must comply with both USP <797> and USP <800>.
2. USP <795> Non-Sterile Compounding: Water Activity (a_w) & Standardized BUD Matrix
The revised USP General Chapter <795> eliminated the legacy distinction between "aqueous oral" and "aqueous topical" formulations. Instead, BUD assignment is determined primarily by water activity (a_w) and whether the preparation contains an antimicrobial preservative.
Scientific Water Activity Thresholds
- Aqueous Formulations (a_w ≥ 0.60): High water activity supports vegetative microbial proliferation, hydrolytic chemical degradation, and fungal growth. These require shorter BUDs and refrigeration if non-preserved.
- Non-Aqueous Formulations (a_w < 0.60): Low water activity inhibits microbial multiplication. These tolerate extended beyond-use dating.
Standardized Non-Sterile Beyond-Use Date (BUD) Table (USP <795>)
| Dosage Form & Formulation Characteristics | Water Activity (a_w) | Storage Conditions | Maximum Beyond-Use Date (BUD) |
|---|---|---|---|
| Non-Preserved Aqueous Dosage Forms<br/>(e.g., reconstituted oral antibiotic suspensions without preservative, unpreserved solutions) | a_w ≥ 0.60 | Refrigerated (2°C to 8°C) | 14 days |
| Preserved Aqueous Dosage Forms<br/>(e.g., oral suspensions containing sodium benzoate, topical creams, preserved lotions) | a_w ≥ 0.60 | Controlled Room Temperature (20°C to 25°C) or Refrigerated | 35 days |
| Non-Aqueous Topical, Dermal, Mucosal & Rectal Forms<br/>(e.g., anhydrous ointments) — see the note below | a_w < 0.60 | Controlled Room Temperature or Refrigerated | 90 days |
| All Other Non-Aqueous Dosage Forms<br/>(e.g., capsules, tablets, powders, troches, ointments, anhydrous creams, gels, pastes, suppositories) | a_w < 0.60 | Controlled Room Temperature or Refrigerated | 180 days |
[!CAUTION] Do not swap the 90-day and 180-day rows. In the current USP <795> table the 90-day ceiling belongs to non-aqueous oral liquids; every other non-aqueous dosage form — including anhydrous topicals such as ointments and non-aqueous creams, gels, and pastes, which older summaries wrongly assign to 90 days — carries the 180-day default.
[!CAUTION] The Component Expiration Override Rule: In no instance may an assigned BUD exceed the shortest expiration date of any individual component, API, or vehicle used in the compound. For example, if a preserved aqueous suspension is compounded on June 1 with a theoretical 35-day BUD (July 6), but the flavoring syrup used has a manufacturer expiration date of June 20, the BUD must be capped at June 20.
3. Master Formulation Record (MFR) vs Compounding Record (CR)
USP <795> and <797> require rigorous two-tier compounding documentation consisting of the Master Formulation Record (MFR) and the Compounding Record (CR).
┌─────────────────────────────────────────────────────────────────────────────┐
│ MFR VS COMPOUNDING RECORD COMPARISON │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Dimension │ Regulatory Distinction (USP <795> / <797>) │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Definition │ MFR: The permanent master "recipe". │
│ │ CR: The batch-specific "execution log". │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ When Created │ MFR: Created BEFORE compounding a preparation for│
│ │ the first time; updated when formula changes. │
│ │ CR: Created EVERY TIME a compound is prepared. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Core Contents │ MFR: Official name, strength, dosage form, all │
│ │ ingredients, mathematical calculations, required │
│ │ equipment, step-by-step instructions, container │
│ │ closure, storage specs, QC checks, BUD rationale.│
│ │ CR: Name/ID of MFR used, actual weights measured,│
│ │ manufacturer lot # and exp date for each API, │
│ │ total yield, Rx #, assigned lot #, BUD assigned, │
│ │ signatures of compounder and verifying RPh. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Tennessee Retention │ Retained on site for at least TWO (2) YEARS. │
└──────────────────────────┴──────────────────────────────────────────────────┘
4. USP <797> Sterile Compounding Framework: Category 1, 2, and 3 CSPs
The revised USP <797> completely replaced the historical "low, medium, and high-risk" scheme with three distinct Categories of Compounded Sterile Preparations (CSPs) based on the environmental controls, testing rigor, and engineering infrastructure under which they are prepared.
┌─────────────────────────────────────────────────────────────────────────────┐
│ USP <797> CSP CATEGORY ARCHITECTURE │
├─────────────────────────────────────────────────────────────────────────────┤
│ CATEGORY 1 CSP: │
│ • Compounded in an unclassified Segregated Compounding Area (SCA) OR suite. │
│ • Primary Engineering Control: ISO Class 5 PEC (LAFW, BSC, CAI). │
│ • Maximum BUD: ≤ 12 hours at room temperature, OR ≤ 24 hours refrigerated. │
│ • Frozen storage is NOT permitted. │
├─────────────────────────────────────────────────────────────────────────────┤
│ CATEGORY 2 CSP: │
│ • Compounded in a certified cleanroom suite (ISO 5 PEC in ISO 7 Buffer). │
│ • Beyond-Use Dates depend on: starting component sterility, terminal │
│ sterilization vs aseptic processing, sterility testing, and temperature. │
│ • Maximum BUD range: 1 day to 45 days (see table below). │
├─────────────────────────────────────────────────────────────────────────────┤
│ CATEGORY 3 CSP: │
│ • Cleanroom suite with enhanced engineering, semi-annual gloved fingertip │
│ and media-fill testing, continuous monitoring, and stability assays. │
│ • Mandatory USP <71> Sterility and USP <85> Endotoxin release testing. │
│ • Extended Beyond-Use Dates: up to 60 to 180 days depending on method. │
└─────────────────────────────────────────────────────────────────────────────┘
Comprehensive Category 2 Beyond-Use Dating (BUD) Table
| Preparation Method & Starting Components | Sterility Testing Status | Controlled Room Temp (20°C to 25°C) | Refrigerated (2°C to 8°C) | Frozen (-25°C to -10°C) |
|---|---|---|---|---|
| Aseptically prepared; all STERILE components | No sterility testing | 4 days | 10 days | 45 days |
| Aseptically prepared; ≥ 1 NON-STERILE component | No sterility testing | 1 day (24 hours) | 4 days | 45 days |
| Terminally sterilized (autoclave); any components | No sterility testing | 14 days | 28 days | 45 days |
| Aseptically prepared or Terminally sterilized | Passing USP <71> Sterility Testing | 28 to 45 days | 45 to 60 days | 60 to 90 days |
Immediate-Use Compounded Sterile Preparations (CSPs)
USP <797> provides an exemption for emergency or clinical crisis situations (e.g., CPR resuscitation, active battlefield trauma, emergent bedside RSI intubation):
- Exemption: May be prepared outside an ISO Class 5 environment (in ambient unclassified air).
- Product Constraints: Maximum of three (3) different sterile commercial drug packages used.
- Aseptic Technique: Requires strict adherence to aseptic technique to the extent possible.
- Administration Deadline: Administration must begin within four (4) hours of the start of preparation (revised up from 1 hour in legacy 2008 standards). If administration has not begun within 4 hours, the preparation must be immediately discarded.
5. USP <800> Hazardous Drug Management: Containment Engineering & Airflow
USP <800> protects healthcare personnel, patients, and the environment from the carcinogenic, teratogenic, reproductive, and genotoxic risks of Hazardous Drugs (HDs), cataloged on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings:
- Group 1: Antineoplastic drugs (e.g., cisplatin, methotrexate, fluorouracil, doxorubicin, paclitaxel).
- Group 2: Non-antineoplastic drugs meeting hazardous criteria (e.g., cyclosporine, azathioprine, carbamazepine).
- Group 3: Drugs with adverse reproductive risks (e.g., finasteride, dutasteride, ribavirin, misoprostol, ganciclovir).
Containment Secondary Engineering Control (C-SEC) Architecture
To prevent the escape of airborne hazardous drug particles or vapors into adjacent pharmacy areas, hazardous compounding must occur in a dedicated Containment Secondary Engineering Control (C-SEC):
┌─────────────────────────────────────────────────────────────────────────────┐
│ USP <800> C-SEC ENGINEERING SPECIFICATIONS │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Engineering Parameter │ Mandatory Statutory Specification │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Air Pressure Regime │ CONTINUOUS NEGATIVE PRESSURE │
│ │ -0.010 to -0.030 inches of water column │
│ │ (-2.5 to -7.5 Pascals) relative to adjacent areas│
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Exhaust Venting │ 100% EXTERNALLY VENTED through dedicated exhaust │
│ │ (never recirculated into the pharmacy or HVAC) │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Air Changes Per Hour │ Sterile C-SEC Cleanroom: Minimum ≥ 30 ACPH │
│ │ Containment SCA (C-SCA): Minimum ≥ 12 ACPH │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Primary Control (C-PEC) │ Class II BSC (Type A2 vented outside, or Type B2)│
│ │ or CACI; 100% external exhaust for sterile HDs. │
└──────────────────────────┴──────────────────────────────────────────────────┘
[!CAUTION] A laminar airflow workbench (LAFW) or standard positive-pressure compounding aseptic isolator (CAI) must NEVER be used for hazardous drug compounding. Positive airflow directly blows hazardous chemical aerosols into the face and breathing zone of the compounding personnel.
6. Closed System Drug-Transfer Devices (CSTDs), PPE & Hazardous Handling
Closed System Drug-Transfer Devices (CSTDs)
A Closed System Drug-Transfer Device (CSTD) is a drug-transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system:
- Compounding: CSTDs are recommended during hazardous drug compounding inside the C-PEC.
- Administration: CSTDs are MANDATORY during the administration of antineoplastic hazardous drugs to patients by nurses or clinical staff when the dosage form allows (e.g., attaching IV tubing to infusion bags).
Mandatory Personal Protective Equipment (PPE) for Hazardous Compounding
- Two Pairs of Chemotherapy Gloves: Must be tested to ASTM D6978 standards, powder-free. The inner glove is worn under the gown cuff; the outer glove is pulled over the gown cuff. Outer gloves must be changed at least every 30 minutes (or immediately if torn, punctured, or contaminated).
- Chemotherapy Gown: Must be disposable, non-permeable (polyethylene-coated or laminated), lint-free, with a solid front (closing in the back) and snug elastic or knit cuffs. Gowns must be changed at least every 2 to 3 hours (or per manufacturer specifications, or immediately after a splash/spill).
- Respiratory Protection: A NIOSH-certified N95 respirator protects against airborne particles but does NOT protect against hazardous vapors or gases. When compounding volatile hazardous drugs or cleaning large spills, a Powered Air-Purifying Respirator (PAPR) or elastomeric half-mask with multi-gas/organic vapor and P100 cartridge is required.
- Eye and Face Protection: Goggles or a full-face shield must be worn when there is a risk of splashing. Standard prescription eyeglasses or safety glasses with side shields are legally inadequate.
- Shoe Covers: Two pairs of shoe covers are required when compounding hazardous drugs. The outer shoe cover must be stripped off inside the negative-pressure C-SEC before stepping into the anteroom to avoid tracking HD residues out.
7. Decontamination, Deactivation, Cleaning, and Disinfection Protocol
Under USP <800>, all areas where hazardous drugs are unpacked, stored, compounded, and dispensed must undergo a rigorous 4-step cleaning sequence:
┌─────────────────────────────────────────────────────────────────────────────┐
│ FOUR-STEP HAZARDOUS CLEANING PROTOCOL │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. DEACTIVATION: │
│ • Renders hazardous chemical compounds inert or inactive. │
│ • Agents: Sodium hypochlorite (bleach), hydrogen peroxide, peracetic acid│
│ │
│ 2. DECONTAMINATION: │
│ • Physically neutralizes and removes hazardous chemical residue. │
│ • Agents: Sterile water, surfactant solutions, sodium thiosulfate. │
│ │
│ 3. CLEANING: │
│ • Removes organic and inorganic material, soil, and particulate matter. │
│ • Agents: Germicidal neutral detergent. │
│ │
│ 4. DISINFECTION: │
│ • Destroys viable microorganisms, vegetative bioburden, and spores. │
│ • Agents: Sterile 70% Isopropyl Alcohol (IPA) or sporicidal disinfectant.│
└─────────────────────────────────────────────────────────────────────────────┘
8. Practical Exam Scenarios
Scenario 1: Assigning BUD to Preserved vs Non-Preserved Formulations
Case: A Nashville compounding pharmacy receives a prescription for pediatric spironolactone 5 mg/mL oral liquid. The pharmacist prepares two alternative formulations for two patients: Formulation A is an aqueous suspension compounded with pure water and flavoring without preservatives; Formulation B is compounded using Ora-Sweet (a preserved aqueous vehicle containing potassium sorbate and methylparaben). Both formulations are stored under refrigeration. Legal Analysis: Under USP <795>, Formulation A is a non-preserved aqueous dosage form (a_w ≥ 0.60), entitling it to a maximum refrigerated BUD of 14 days. Formulation B is a preserved aqueous dosage form (a_w ≥ 0.60 with antimicrobial preservatives), entitling it to a maximum BUD of 35 days at refrigerated or controlled room temperature (provided no API component expires sooner).
Scenario 2: Emergent Compounding in a Segregated Compounding Area (SCA)
Case: A community oncology pharmacy in Knoxville prepares an intravenous bag of vancomycin in an ISO Class 5 laminar airflow workbench located inside a designated Segregated Compounding Area (SCA) with unclassified ambient room air. The compounding technician labels the product with a Beyond-Use Date of 7 days under refrigeration. Legal Analysis: Under USP <797>, sterile preparations prepared in a Segregated Compounding Area (outside a classified cleanroom suite) are designated as Category 1 CSPs. The statutory BUD ceiling for a Category 1 CSP is ≤ 12 hours at controlled room temperature or ≤ 24 hours under refrigeration. Assigning a 7-day refrigerated BUD violates USP <797> and Tennessee Board rules. The product must be re-labeled for use within 24 hours under refrigeration or discarded.
Scenario 3: Hazardous Antineoplastic Administration Without CSTD
Case: A hospital clinic nurse administers an intravenous fluorouracil infusion to a chemotherapy patient. The clinic director instructs nurses to connect standard non-closed secondary IV sets to save costs, arguing that Closed System Drug-Transfer Devices (CSTDs) are only mandatory inside the pharmacy compounding hood. Legal Analysis: Under USP <800>, CSTDs are recommended during compounding inside the C-PEC, but are MANDATORY during the administration of antineoplastic hazardous drugs when the dosage form allows. The clinic policy directly violates USP <800>, exposing healthcare personnel to hazardous antineoplastic aerosolization and needle-stick contamination.
Under revised USP <795>, a compounding pharmacist prepares an oral aqueous suspension of omeprazole that contains no antimicrobial preservative agents. If all active pharmaceutical ingredients have manufacturer expiration dates exceeding one year, what is the maximum permissible Beyond-Use Date (BUD) when stored under refrigeration (2°C to 8°C)?
A hospital satellite pharmacy prepares a parenteral cefazolin intravenous piggyback in an ISO Class 5 laminar airflow workbench situated within an unclassified Segregated Compounding Area (SCA). Under USP <797>, how is this compounded sterile preparation classified, and what is its maximum permissible Beyond-Use Date?
A compounding pharmacy is designing a new cleanroom suite for preparing sterile antineoplastic chemotherapy infusions under USP <800>. What engineering specifications must the Containment Secondary Engineering Control (C-SEC) meet regarding airflow, pressure differential, and exhaust?
A clinical oncology nurse is administering an intravenous infusion of doxorubicin (an antineoplastic hazardous drug) to a hospital patient, and a compounding technician is preparing a batch of paclitaxel inside a Class II BSC. Which of the following statements correctly identifies the PPE and CSTD requirements under USP <800>?